# YORVIPATH (palopegteriparatide) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/palopegteriparatide

> The FDA approved YORVIPATH (palopegteriparatide), sponsored by Ascendis Pharma A/S (ASND), on Aug 2024 for hypoparathyroidism in adults.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | YORVIPATH (palopegteriparatide) |
| Codes |  |
| Sponsor | Ascendis Pharma A/S (ASND) https://sec-api.dev/companies/asnd/catalysts |
| Indications | [hypoparathyroidism in adults](https://sec-api.dev/indications/hypoparathyroidism-in-adults), [Hypoparathyroidism](https://sec-api.dev/indications/hypoparathyroidism) |
| Modality | peptide |
| FDA designations | orphan |

## Timeline

### Aug 2024: FDA approval

- Status: completed, approved. Date confidence: month. Indication: hypoparathyroidism in adults.
- First seen 2025-04-29, last confirmed 2026-05-07.
- SEC Form 8-K (accession 0001612042-26-000005): "In August 2024, the FDA approved YORVIPATH (palopegteriparatide; developed as TransCon PTH) for the treatment of hypoparathyroidism in adults." https://www.sec.gov/Archives/edgar/data/1612042/000161204226000005/asnd-20260331.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-063954): "In August 2024, the FDA approved YORVIPATH (palopegteriparatide; developed as TransCon PTH) for the treatment of hypoparathyroidism in adults." https://www.sec.gov/Archives/edgar/data/1612042/000119312526063954/d112586dex992.htm
- SEC Form 8-K (accession 0001193125-25-277622): "In August 2024, the FDA approved YORVIPATH (palopegteriparatide; developed as TransCon PTH) for the treatment of hypoparathyroidism in adults." https://www.sec.gov/Archives/edgar/data/1612042/000119312525277622/asnd-20250930.htm
- SEC Form 8-K (accession 0001612042-25-000006): "In August 2024, the FDA approved YORVIPATH (palopegteriparatide; developed as TransCon PTH) for the treatment of hypoparathyroidism in adults." https://www.sec.gov/Archives/edgar/data/1612042/000161204225000006/asnd-20250630.htm
- SEC Form 8-K (accession 0000950170-25-061850): "In August 2024, the FDA approved YORVIPATH (palopegteriparatide; developed as TransCon PTH) for the treatment of hypoparathyroidism in adults." https://www.sec.gov/Archives/edgar/data/1612042/000095017025061850/asnd-20250331.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-103766): "In August 2024, the FDA approved YORVIPATH® (palopegteriparatide; developed as TransCon PTH) for the treatment of hypoparathyroidism in adults." https://www.sec.gov/Archives/edgar/data/1612042/000119312525103766/d75062dex992.htm

### August 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Hypoparathyroidism.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07706764 (A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Ascendis Pharma A/S." https://clinicaltrials.gov/study/NCT07706764

### Aug to Nov 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Hypoparathyroidism.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07706764 (A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Ascendis Pharma A/S." https://clinicaltrials.gov/study/NCT07706764

## Same indication

- [TransCon (transcon)](https://sec-api.dev/pdufa/transcon) (ASND)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/palopegteriparatide.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "YORVIPATH (palopegteriparatide) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/palopegteriparatide

```bibtex
@misc{secapidev_pdufa_palopegteriparatide_20261116,
  title        = {YORVIPATH (palopegteriparatide) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/palopegteriparatide}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_palopegteriparatide_20261116","title":"YORVIPATH (palopegteriparatide) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/palopegteriparatide","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
